In a groundbreaking development, researchers at the Institute of Advanced Study in Science and Technology (IASST) in Guwahati have discovered that Selegiline, an antidepressant drug, holds potential for repurposing as an effective treatment for breast cancer. The research team, led by Dr. Asis Bala, has shown that Selegiline, a monoamine oxidase (MAO) inhibitor, could offer a cost-effective therapeutic option for breast cancer management.

Drug repurposing, a method increasingly used by biomedical scientists, offers a faster and more economical alternative to developing new drugs, which often involve expensive and lengthy processes. Dr. Bala’s team has been at the forefront of this approach, aiming to develop improved strategies for cancer treatment.

The study revealed that Selegiline interacts with ten genes intricately linked to various types of cancer, showing significant effectiveness in killing estrogen and progesterone-positive (ER+ & PR+) breast cancer cells as well as triple-negative breast cancer (TNBC) cells. Notably, Selegiline induces cell death in these cancer cells through a mechanism that does not rely on reactive oxygen species (ROS). Additionally, the drug inhibits protein kinase C phosphorylation, a process that may contribute to its anticancer effects.

The findings of this study, published in the journal Medical Oncology, highlight the potential of Selegiline as an anticancer agent, marking a significant milestone in cancer research. However, further investigation is required to assess its in vivo efficacy, optimize dosage, and evaluate potential contraindications and adverse side effects.

Dr. Bala’s research is the first of its kind to explore the use of Selegiline for breast cancer treatment, opening new avenues for cost-effective cancer therapies. This discovery could pave the way for more accessible treatment options for breast cancer patients, significantly impacting the future of cancer care.